Citadel Advisors
DWTX

Citadel Advisors’s Dogwood Therapeutics DWTX Stock Holding History

Citadel Advisors’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,496
Closed -$8.83K – 15661
2022
Q4 		$8.83K Sell
1,496
-1,992
-57% -$15K ﹤0.01% 13726
2022
Q3 		$33K Buy
+3,488
New +$492K ﹤0.01% 11855

Other funds holding DWTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's DWTX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Dogwood Therapeutics (DWTX) in Q2 2026: 11,742 shares worth $18.9K. The stake represents ﹤0.01% of the portfolio and ranks #13414 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in DWTX as recently as Q2 2023.

Citadel Advisors first reported a position in DWTX in Q2 2021 and has held it in 3 quarters since. The position peaked at $64K in Q2 2021. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • Citadel Advisors held 11,742 shares of Dogwood Therapeutics worth $18.9K as of Q2 2026.
  • Dogwood Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Dogwood Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13414 holding.
  • Citadel Advisors first reported a position in Dogwood Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • Citadel Advisors's Dogwood Therapeutics position peaked at $64K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.